BOSTON —Small interfering RNA technology has the potential to become a novel treatment approach in cardiovascular medicine, according to Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA. In this ...

Molecular Instruments® (MI), the inventor of the HCR™ platform, today announced key enhancements to its HCR™ Gold and HCR™ Pro product lines. These upgrades include next-generation chemistry for ...

Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, typically 20-25 base pairs in length, that play a crucial role in the RNA interference (RNAi) pathway. siRNAs are involved in ...

Lepodisiran is a small interfering RNA inhibitor designed to inhibit the production of Lp (a).The ALPACA phase 2 trial enrolled 320 participants with Lp (a) levels of 175 nmol/L or higher.

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

Study: Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. Image Credit: peterschreiber.media / Shutterstock.com The role of lipoproteins in cardiovascular diseases ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...